Experience of gemcitabine combined with oxaliplatin (GemOx) for matastatic pancreatic adenocarcinoma

• MATSUDA Masamichi

  Department of Surgery, Toranomon Hospital

• WATANABE Goro

  Department of Surgery, Toranomon Hospital

• HASHIMOTO Masaji

  Department of Surgery, Toranomon Hospital

Bibliographic Information

Other Title

• 進行すい癌に対するＧｅｍｃｉｔａｂｉｎｅ，Ｏｘａｌｉｐｌａｔｉｎ併用療法（ＧｅｍＯｘ）の経験

Abstract

A 51-year-old man was admitted to our hospital for treatment of advanced pancreatic carcinoma. During surgery, several small liver metastases were discovered, and intraoperative electron beam irradiation (20 Gy) was performed for the main tumor with microwave coagulation carried out for the metastatatic sites. Postoperatively, the patient received gemcitabine 800 mg as a 10 mg/m²/min infusion followed by oxaliplatin 100 mg as a 1-hour infusion every 2 weeks. As the incidence of neurosensory disorders such as paresthesia of the lip or extremities increased with the number of courses administered, the gemcitabine-oxaliplatin regimen (GemOx) had to be stopped after ten courses. Neither nephrotoxicity nor hematologic toxicity was observed. The outpatient GemOx regimen was well tolerated by the patient. We believe that this case report demonstrates both the potential efficacy and side effects of GemOx for treatment of pancreatic carcinoma.

Journal

• Suizo

  Suizo 20 (6), 554-559, 2005

  Japan Pancreas Society

Keywords

• Oxaliplatin
• Gemcitabine

Details

• CRID: 1390001204639656064
• NII Article ID: 10018039559
• NII Book ID: AN10043798
• DOI: 10.2958/suizo.20.554
• ISSN: 18812805
• ISSN: 09130071
• Web Site: https://search.jamas.or.jp/link/ui/2006151565
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed